Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
| Status: | Archived |
|---|---|
| Conditions: | Lung Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2009 |
A Phase I/II Study of RAD001 and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Radiation therapy uses
high-energy x-rays to kill tumor cells. Giving everolimus together with whole-brain
radiation therapy may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of everolimus and
to see how well it works when given together with whole-brain radiation therapy in treating
patients with brain metastasis from non-small cell lung cancer.
OBJECTIVES:
Primary
- To determine the maximum-tolerated dose of everolimus when combined concurrently with
whole-brain radiotherapy in patients with brain metastasis from stage IV non-small cell
lung cancer. (Phase I)
- To evaluate the median survival of these patients treated with this regimen. (Phase II)
Secondary
- To assess the response rates in these patients. (Phase II)
- To assess the safety and tolerability of this regimen in these patients. (Phase II)
- To determine time to CNS (neurological) progression, confirmed by MRI, in these
patients. (Phase II)
- To determine time to systemic (non-CNS) progression in these patients. (Phase II)
OUTLINE: This is a multicenter, dose-escalation study of everolimus.
Patients undergo 10 fractions of whole-brain radiotherapy (WBRT) beginning on day 0, 5 days
per week, and receive oral everolimus once daily on days -1 to 13. Beginning 2 weeks after
completion of WBRT, patients receive oral everolimus once daily for 28 days in the absence
of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 2 months for 2 years.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials